{"entity":{"id":"araris","kind":"company","name":"Araris Biotech (Taiho)","aka":[],"tldr":"Swiss linker-technology company (AraLinQ) acquired by Taiho for up to $1.14B; first clinical ADC ARC-02 (CD79b) dosed in June 2026.","summary":"Araris Biotech, based in Zurich, is the Swiss linker-technology company behind AraLinQ, acquired by Taiho for up to 1.14 billion dollars, and its first clinical ADC, ARC-02, was dosed in June 2026. Taiho paid 400 million dollars at closing in 2025 with up to 740 million dollars in milestones, and ARC-02, a CD79b-targeted MMAE ADC built with AraLinQ site-specific conjugation, entered phase 1 in non-Hodgkin lymphoma in June 2026 as the first AraLinQ product in humans. OnCo links it to diffuse large B-cell lymphoma, to ADCs and site-specific conjugation and linker chemistry, to Taiho, and to the idea of platform designation for ADC linker-payloads so manufacturing data carry across. Whether a cleaner linker changes clinical outcomes, or only manufacturing, is the question ARC-02 will start to answer. Taiho has its own page.","asOf":"2026-09-04","links":[{"label":"ARC-02 phase 1","url":"https://www.taiho.co.jp/en/release/2026/20260428.html"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":["adcs"],"technologies":["adc","site-specific-conjugation"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct02503423","nct07710885","nct05945823","nct04256317","nct04683250","nct05727176","nct05967689"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Zurich","country":"CH","companyType":"biotech","website":"https://www.ararisbiotech.com","investors":[],"funding":[]},"route":"/companies/araris/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/"}],"trial":[{"id":"nct04256317","kind":"trial","name":"A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)","route":"/trials/nct04256317/"},{"id":"nct05967689","kind":"trial","name":"A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.","route":"/trials/nct05967689/"},{"id":"nct07710885","kind":"trial","name":"Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct07710885/"},{"id":"nct02503423","kind":"trial","name":"Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas","route":"/trials/nct02503423/"},{"id":"nct05945823","kind":"trial","name":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","route":"/trials/nct05945823/"},{"id":"nct05727176","kind":"trial","name":"Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement","route":"/trials/nct05727176/"},{"id":"nct04683250","kind":"trial","name":"Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities","route":"/trials/nct04683250/"}],"company":[{"id":"taiho","kind":"company","name":"Taiho Pharmaceutical (Otsuka)","route":"/companies/taiho/"}],"idea":[{"id":"idea-reg-adc-platform-designation","kind":"idea","name":"Platform designation for ADC linker-payloads so manufacturing data carry across","route":"/ideas/idea-reg-adc-platform-designation/"}],"roadmap":[{"id":"drug-discovery-roadmap","kind":"roadmap","name":"Drug discovery roadmap: screening in mice → maps of dependency → designing in silico","route":"/roadmaps/drug-discovery-roadmap/"}]}}